Ashland Finalizes Key Divestment: What the Avoca Sale Means for Growth – StockTitan

Please enter your login and password
Forgot password?
Don’t have an account? Sign Up!
Please enter your email address
To create a free account, please fill out the form below.
Already have an account? Login
NaaS Technology Inc. and Xiaomi Auto Join Forces to Enhance Smart…
AirNet Announces Entry into Non-Biding Investment Letter of Inten…
Faraday Future Establishes the World’s First AI Hybrid Extended-R…
Gemini Priming Attenuates Inflammation in Human Peripheral Blood …
Precision BioSciences Announces Clearance of Investigational New …
Castellum Announces Pricing of $4.5 Million Public Offering of Co…
NaaS Technology Inc. and Xiaomi Auto Join Forces to Enhance Smart…
AirNet Announces Entry into Non-Biding Investment Letter of Inten…
Faraday Future Establishes the World’s First AI Hybrid Extended-R…
Gemini Priming Attenuates Inflammation in Human Peripheral Blood …
Precision BioSciences Announces Clearance of Investigational New …
Castellum Announces Pricing of $4.5 Million Public Offering of Co…
Ashland Inc. (NYSE: ASH) has completed the sale of its Avoca business to Mane on March 14, 2025. The Avoca business, which represents the final entity from Ashland’s previous Pharmachem acquisition, specializes in producing sclareolide (a fragrance fixative) and offers contract manufacturing capabilities through facilities in North Carolina and Wisconsin.
While financial terms were not disclosed, the transaction marks a strategic divestment for Ashland. The deal transfers Avoca’s manufacturing facilities and its workforce to Mane, whose CEO Samantha Mane expressed commitment to ingredient production through this acquisition. Squire Patton Boggs served as Ashland’s legal advisor for the transaction.
Ashland Inc. (NYSE: ASH) ha completato la vendita della sua attività Avoca a Mane il 14 marzo 2025. L’attività Avoca, che rappresenta l’ultima entità dell’acquisizione Pharmachem di Ashland, è specializzata nella produzione di sclareolide (un fissativo per fragranze) e offre capacità di produzione a contratto attraverso impianti in Carolina del Nord e Wisconsin.
Sebbene i termini finanziari non siano stati divulgati, la transazione segna un disinvestimento strategico per Ashland. L’accordo trasferisce gli impianti di produzione di Avoca e il suo personale a Mane, il cui CEO Samantha Mane ha espresso impegno per la produzione di ingredienti attraverso questa acquisizione. Squire Patton Boggs ha fungito da consulente legale per Ashland nella transazione.
Ashland Inc. (NYSE: ASH) ha completado la venta de su negocio Avoca a Mane el 14 de marzo de 2025. El negocio Avoca, que representa la última entidad de la adquisición Pharmachem de Ashland, se especializa en la producción de sclareolida (un fijador de fragancias) y ofrece capacidades de fabricación por contrato a través de instalaciones en Carolina del Norte y Wisconsin.
Aunque los términos financieros no fueron divulgados, la transacción marca una desinversión estratégica para Ashland. El acuerdo transfiere las instalaciones de fabricación de Avoca y su fuerza laboral a Mane, cuyo CEO, Samantha Mane, expresó su compromiso con la producción de ingredientes a través de esta adquisición. Squire Patton Boggs actuó como asesor legal de Ashland para la transacción.
Ashland Inc. (NYSE: ASH)는 2025년 3월 14일 Mane에 Avoca 사업의 매각을 완료했습니다. Avoca 사업은 Ashland의 이전 Pharmachem 인수에서 마지막으로 남은 실체로, 향수 고정제인 스클레롤리드를 생산하며 노스캐롤라이나와 위스콘신에 있는 시설을 통해 계약 제조 능력을 제공합니다.
재무 조건은 공개되지 않았지만, 이번 거래는 Ashland에 대한 전략적 매각을 의미합니다. 이 거래는 Avoca의 제조 시설과 인력을 Mane에 이전하며, Mane의 CEO인 Samantha Mane는 이번 인수를 통해 원료 생산에 대한 의지를 표명했습니다. Squire Patton Boggs는 이번 거래에 대해 Ashland의 법률 자문 역할을 수행했습니다.
Ashland Inc. (NYSE: ASH) a finalisé la vente de son activité Avoca à Mane le 14 mars 2025. L’activité Avoca, qui représente la dernière entité de l’acquisition Pharmachem d’Ashland, est spécialisée dans la production de sclareolide (un fixatif pour parfums) et offre des capacités de fabrication sous contrat grâce à des installations en Caroline du Nord et au Wisconsin.
Bien que les conditions financières n’aient pas été divulguées, la transaction marque un désinvestissement stratégique pour Ashland. L’accord transfère les installations de production d’Avoca et son personnel à Mane, dont la PDG, Samantha Mane, a exprimé son engagement envers la production d’ingrédients à travers cette acquisition. Squire Patton Boggs a été le conseiller juridique d’Ashland pour cette transaction.
Ashland Inc. (NYSE: ASH) hat am 14. März 2025 den Verkauf seines Avoca-Geschäfts an Mane abgeschlossen. Das Avoca-Geschäft, das die letzte Einheit aus der früheren Pharmachem-Akquisition von Ashland darstellt, ist auf die Produktion von Sclareolid (einem Duftfixativ) spezialisiert und bietet Vertragsfertigungskapazitäten durch Einrichtungen in North Carolina und Wisconsin an.
Obwohl die finanziellen Bedingungen nicht offengelegt wurden, stellt die Transaktion eine strategische Desinvestition für Ashland dar. Der Deal überträgt die Produktionsstätten und die Belegschaft von Avoca an Mane, dessen CEO Samantha Mane ihr Engagement für die Produktion von Inhaltsstoffen durch diese Akquisition zum Ausdruck brachte. Squire Patton Boggs fungierte als rechtlicher Berater von Ashland für die Transaktion.
Wilmington, Del., March 17, 2025 (GLOBE NEWSWIRE) — Ashland Inc. (NYSE: ASH) announced today that it has completed the sale of its Avoca business to Mane effective March 14, 2025. Financial terms of the transaction were not disclosed.
The Avoca business supplies sclareolide, a fragrance fixative, and a range of contract manufacturing capabilities from two production facilities in North Carolina and Wisconsin.  The Avoca business line represents the last entity from Ashland’s previous acquisition of Pharmachem.
“The Avoca business is a strong player in the fragrance fixative space, with a dedicated team and attractive manufacturing capabilities to meet customer needs,” said Guillermo Novo, chair and chief executive officer, Ashland. “I want to thank the Avoca employees for their dedication and commitment to Ashland and to our customers. On behalf of the Ashland team, I wish them continued success as part of Mane.”
“I am pleased to announce the acquisition of the Avoca sites from Ashland, reinforcing our commitment to the production of ingredients for our industry,” said Samantha Mane, CEO of MANE.
Squire Patton Boggs is acting as legal advisor to Ashland.
About Ashland 
Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, personal care and pharmaceutical. Approximately 3,200 passionate, tenacious solvers thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more. 
About Mane
Founded in 1871 by Victor Mane, MANE is one of the leading producers and suppliers of fragrances and flavours globally. Since inception, the company has been owned and managed by five successive generations of the Mane family.
MANE is a global group, operating 29 production facilities worldwide and more than 79 sites in more than 40 countries and employing over 8,000 collaborators.  The first French company and the fifth largest fragrances and flavours producer in the world and are recognised as the fastest growing major company within the industry.  In 2023, MANE generated revenues of above €1,770 million.
^™ Trademark, Ashland or its subsidiaries, registered in various countries.
FOR FURTHER INFORMATION:

Attachment
© 2020-2025 StockTitan.net

source